[REQ_ERR: 404] [KTrafficClient] Something is wrong. Enable debug mode to see the reason.

Destiny-breast03 clinicaltrials.gov

Background: Methods: We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 . Mar 24,  · Abstract. Management. Nausea and vomiting. DESTINY-Breast03, % (/) and %. (/) [grade!3. Frequency in clinical trials of breast cancer. Aug 9, In DESTINY-Breast03, Enhertu also showed a strong trend toward improved For more information about the trial, visit rainer-daus.de . DSa Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. DSa Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. We conducted DESTINY-Breast03, a phase 3, multicenter, open-label, randomized, active-controlled trial, to evaluate the efficacy and safety of trastuzumab deruxtecan as compared . In DESTINY-Breast03, drug-related AEs occurred in % of patients ( of ), Event, Frequency in clinical trials of breast cancer, Management.

  • Background: In the DESTINY-Breast03 (NCT) primary analysis (data cutoff [DCO], May 21, ), T-DXd showed superiority over T-DM1 in pts with HER2+  .
    • additional cancer types. DESTINY Clinical Trials. A series of international trials investigating trastuzumab deruxtecan (T-DXd)* as a potential. Select a cancer type to learn more about current clinical trials. treatment option for eligible patients with certain cancers, including breast, gastric, lung, and. This study will examine trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive primary BC who have residual invasive disease in breast or axillary lymph nodes with higher risk of recurrence, which includes patients who were inoperable at disease presentation or had pathological node-positive status after neoadjuvant therapy. . Clinical trials are part of clinical research that look at new ways to prevent, detect, or treat disease. Clinical trials can help to determine if new medicines are tolerated and effective. Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]. The list below, as well as information from Daiichi Sankyo Group-sponsored clinical trials registered and published on registries such as rainer-daus.de  . A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08). Lung-specific intercurrent clinically significant illnesses Uncontrolled or significant cardiovascular disease or infection Prior documented interstitial lung disease (ILD)/ pneumonitis that required steroids, current ILD/ pneumonitis, or suspected ILD/ pneumonitis that cannot be ruled out by imaging at screening. Daiichi Sankyo, Inc. and AstraZeneca are providing this service to help patients . Any approved products should be used in accordance with their product labeling (or Prescribing Information). 4 dic Clinical Trials / rainer-daus.de Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]. Jul 7, In this interview, Dr King also discusses important data from longer term data presented from DESTINY-Breast03 (), and also the phase 3  . (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast03 rainer-daus.de number, NCT). Treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis. Please refer to this study by its rainer-daus.de identifier (NCT number): NCT Locations Show study locations. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. The DESTINY-Breast03 study, a randomized, phase III trial pitting the antibody-drug conjugates trastuzumab emtansine and trastuzumab deruxtecan against each other in HER2+ . Abstract. The list below, as well as information from Daiichi Sankyo Group-sponsored clinical trials registered and published on registries such as rainer-daus.de rainer-daus.de DSa Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously  . QUICK TAKE Trastuzumab Deruxtecan for Breast Cancer (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast03 rainer-daus.de number, NCT) Introduction. They are important as they, in many cases, may lead to medical advances and further understanding of potential treatment options for people. Clinical trials are part of clinical research that look at new ways to prevent, detect, or treat disease. Clinical trials can help to determine if new medicines are tolerated and effective. Ongoing Clinical Trials| February 15 breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03). May 5, The approval was based on data from the phase 3 DESTINY-Breast03 trial (rainer-daus.de Identifier: NCT), which included   . Methods Trial Design We conducted DESTINY-Breast03, a phase 3, multi - center, open-label, randomized, active-controlled trial, to evaluate the efficacy and safety of tras-. DESTINY-Breast03 trial. One patient with prior T-DM1 treatment was enrolled in error in the ENHERTU arm. DESTINY-Breast03 is the first and only head-to-head study of ENHERTU vs T-DM1 2 Patient demographics were balanced between treatment arms Select baseline patient demographics and disease characteristics 2,3 All patients received at least 1 prior cancer therapy. Background: In the DESTINY-Breast03 (NCT) primary analysis (data cutoff [DCO], May 21, ), T-DXd showed superiority over T-DM1 in pts with HER2+. . and the DESTINY-Breast03 (rainer-daus.de identifier: NCT) is a randomized, open- label study of DSa versus T-DM1 for patients.
  • Methods: We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
    • We conducted DESTINY-Breast03, a phase 3, multi - center, open-label, randomized, active-controlled trial, to evaluate the efficacy and safety of tras- tuzumab deruxtecan as compared with trastuzu. The overall survival (OS) data from DESTINY-Breast03 are immature; NCT rainer-daus.de Apr 12, The overall survival (OS) data from DESTINY-Breast03 are immature; NCT rainer-daus.de . The trial was funded by Daiichi Sankyo, Inc., and AstraZeneca, the developers of T-DXd. The new study, a large international clinical trial called DESTINY-Breast03, is the first to directly compare T-DXd with another treatment in people with breast cancer. Nearly 90% of participants had hormone receptor -positive disease, meaning their tumors had receptors for the hormones estrogen and/or progesterone. The clinical trial, called DESTINY-Breast04, enrolled adults who had metastatic or inoperable HER2-low breast cancer and had previously been treated with one or two types of chemotherapy. [second line]; rainer-daus.de identifier NCT ), and DESTINY-Breast04 (HER2-low MBC;. DESTINY-Breast03 (trastuzumab deruxtecan vs T-DM1. Daiichi Sankyo, Inc. and AstraZeneca are providing this service to help patients and physicians find clinical trial site locations and contact information for T-DXd. Please note that this locator tool shows clinical trial site locations. Any approved products should be used in accordance with their product labeling (or Prescribing Information). QUICK TAKE Trastuzumab Deruxtecan for Breast Cancer (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast03 rainer-daus.de number, NCT) Introduction.